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Overview of Drug Development
Summary
• Drug development costs range from $2 to $3 billion and may span from 7 to 12 years.
• Beginning with drug discovery, key steps in the process include preclinical testing, Phase 1–3 clinical
trials, FDA New Drug Application (NDA) approval, and subsequent Phase 4 clinical research.
• Academic entrepreneurs should understand the unique needs of each phase and their potential role in
the process, as well as the services their academic medical center can provide.
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Summary 
● Drug development costs range from $2 to $3 billion and may span from 7 to 12 years. 
● Beginning with drug discovery, key steps in the process include preclinical testing, Phase 1–3 
clinical trials, FDA New Drug Application (NDA) approval, and subsequent Phase 4 clinical 
research. 
● Academic entrepreneurs should understand the unique needs of each phase and their potential 
role in the process, as well as the services their academic medical center can provide. 
Introduction 
Drug development is one of several cornerstones of advancing medical care. The process is com-
plicated, expensive, and can span over a decade. An academic entrepreneur has several crucial 
roles to play throughout the process, and the resources available at academic centers—such as 
NIH-funded Clinical and Translational Science Awards (CTSA) and the tech transfer office—can 
often significantly contribute as well. In this chapter, we will provide an overview of the drug 
development process and the steps required to successfully bring a new compound from discovery 
to clinical practice. Other chapters provide information about specific subtypes of compounds, 
such as orphan drugs (“Orphan Drugs: Understanding the FDA Approval Process”), biologics 
(“Intellectual Property Protection for Biologics”), or radiographic agents (“Development of Radi-
ographic Contrast Agents for Diagnostic Imaging”).  
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Background 
The Food and Drug Administration (FDA) approves approximately twenty–fifty new compounds 
each year, with 2018 seeing fifty-nine approvals (Figure 1), an unusually high number (Mullard). 
However, these simple numbers belie an important fact: drug approval is a costly and uncertain 
endeavor. The average cost of a new drug approval is $2–$3 billion, and only 14% of drugs that 
enter clinical trials eventually obtain FDA approval (DiMasi et al.; Wong et al.). This journey, 
from invention to clinical application in patients, can take from 7 to 12 years for a drug, compared 
to three to seven years for a device (Van Norman). Despite these daunting prospects, the task of 
drug development is crucial for advancing healthcare. New medications, along with several other 
key innovations in public health and other domains, have meaningfully contributed to the substan-
tial increases in quality of life, functional status, and lifespan that have occurred over the past 
century.  
 
Figure 1. FDA Drug Approvals per Year. 
 
 
Source: Adapted from Mullard. Does not include vaccines. 
Discovery 
Drug discovery can occur through different pathways. These include 1) repurposing an existing 
molecule; 2) creating variants of an existing molecule (such as through cis/trans isomers); 3) iden-
tifying a molecule that acts on a specific biochemical pathway (perhaps one that the academic 
entrepreneur has been researching), or 4) finding a new compound in nature that can be used in 
humans or animals. Once identified, these compounds typically undergo a rigorous drug design 
process, as shown in Figure 2. Subsequently, they can be produced under Current Good 
Manufacturing Practice (CGMP) regulations, which are enforced by the FDA, culminating in an 
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optimized candidate compound for subsequent evaluation in further preclinical (i.e., animal) and 
human studies. 
 
Figure 2. Drug Design. 
  
Source: Adapted from “Drug Design,” Wikipedia (Wikipedia contributors). 
 
After the initial discovery phase, the compound may move on to additional FDA-required preclin-
ical testing. Note that if an academic entrepreneur has the potential to benefit financially from the 
compound, either through licensing revenue or equity in a company that owns the compound or 
plans to develop it, some universities may require that the academic entrepreneur modify their role 
in regards to any research that may subsequently be included in FDA documents, starting with 
preclinical studies and extending through all phases of development (see the chapter “Understand-
ing Conflict of Interest for Academic Entrepreneurs”). This may include relinquishing the principal 
investigator role and hiring an independent party to conduct the relevant research or audit the work. 
The first step in determining the appropriate measures is to contact the university’s conflict-of-
interest committee prior to conducting any preclinical or clinical research that may be included in 
an FDA submission; this can avoid the costly outcome of repeating the work and subsequent delays 
in the FDA Investigational New Drug (IND) submission.  
 
Since the steps below are primarily targeted toward obtaining FDA approval, it is crucial to engage 
with the FDA throughout the drug development process to make sure that the research studies are 
collecting the necessary data, and that there are no unanticipated surprises in terms of the need to 
conduct additional research studies (Figure 3). 
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Figure 3. FDA Interactions During Drug Development. 
 
 
Source: Image downloaded from Wikimedia Commons and provided by the FDA:  
https://commons.wikimedia.org/wiki/File:The_extensive_industry-
FDA_interactions_that_occur_during_product_development,_using_the_drug_development_pro
cess_as_a_specific_example.gif. 
 
One particularly useful tool for conducting this engagement and ensuring that the subsequent 
development process is timely and efficient is a Target Product Profile (TPP). As described by the 
FDA, the goal of a “TPP is to provide a format for discussions between a sponsor and the FDA 
that can be used throughout the drug development process, from pre-investigational new drug ap-
plication (pre-IND) or investigational new drug application (IND) phases of drug development 
through postmarketing programs to pursue new indications or other substantial changes in labeling. 
The TPP embodies the notion of beginning with the goal in mind. That is, the sponsor specifies 
the labeling concepts that are the goals of the drug development program, documents the specific 
studies intended to support the labeling concepts, and then uses the TPP to assist in a constructive 
dialogue with the FDA. The ideal version of what the sponsor would like to claim in labeling 
guides the design, conduct, and analysis of clinical trials to maximize the efficiency of the devel-
opment program” (Guidance for Industry and Review Staff Target Product Profile—A Strategic 
Development Process Tool). 
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Preclinical Studies 
Preclinical studies are in vivo studies that usually occur in animals. Initially, they are conducted in 
animals without the disease of interest in order to test toxicology, then later in animal models of 
the disease that allow for assessment of disease-modifying effects. The purpose of this research is 
to obtain FDA approval for an IND that will in turn allow for subsequent research in human sub-
jects. Testing must typically occur in two different mammalian species, as per FDA guidelines. 
The tests are often conducted by a center with expertise in this area; academic centers with 
veterinary schools may offer this service, as well as specialized outside companies (see the chapter 
“Preclinical Animal Models”).  
 
Note that the core preclinical studies must be completed before the compound is given to any 
human subjects. These studies can help determine the no-observed-adverse-effect levels 
(NOAELs) for the compound, which are necessary to identify the initial dose level of the 
compound for subsequent Phase 1 human clinical trials (first-in-man). Failure to follow FDA 
guidelines for conducting preclinical evaluations may result in an IND application being rejected, 
and culminate in the need to repeat the testing, potentially leading to significant delays in drug 
development. These FDA guidelines include rigorous quality control, oversight, and comprehen-
sive reporting of results. This can be particularly challenging for academic entrepreneurs because, 
in some cases, this initial work would have been done in an exploratory capacity and thus may not 
meet FDA guidelines. On average, the preclinical phase can take three and a half years (“Drug 
Approvals - From Invention to Market...12 Years!”). 
 
It is also worth noting that these preclinical studies may suggest a potential role for the compound 
in animal diseases and thus a veterinary medicine application for the compound. This offers several 
important benefits, including the potential to gather additional safety data and faster access to the 
veterinary market as compared to human applications, which can lead to revenue from sales in the 
veterinary medicine market that may support further development in humans. These opportunities 
are described in more detail in the chapter “Development Strategies for Animal Medical 
Therapeutics.” 
Investigational New Drug Application 
Once the compound can be manufactured with optimal quality control, and once a sufficient body 
of evidence is accumulated from preclinical testing, the pharmaceutical company will next move 
to filing an Investigational New Drug (IND) application with the FDA. The purpose of an IND is 
to allow the FDA to evaluate the compound and determine if it is safe to begin testing the com-
pound in humans. The FDA has 30 days to review the IND, and may request additional information 
that may require additional preclinical research and substantially delay approval of the IND, thus 
early engagement with the FDA to map out or review the preclinical testing prior to submitting the 
IND is highly recommended. The IND also includes detailed information about the planned human 
5https://repository.upenn.edu/ace/vol1/iss3/16
  
OVERVIEW OF DRUG DEVELOPMENT 
 
subject studies (Phases 1–3), and is often also reviewed by the institutional review board (IRB), 
which will be overseeing those studies. Additional details regarding the IND application are pro-
vided in the chapter “FDA Drug Regulation: Investigational New Drug Applications.” 
Phase 1 Clinical Research 
After an IND has been approved by the FDA, or 30 days have elapsed since submission to the 
FDA without comment, the pharmaceutical company may begin testing in human subjects in Phase 
1 trials. These studies typically involve 20 to 60 healthy volunteer participants. Starting with the 
NOAEL, adjusting for a safety factor, small groups are tested at sequentially higher doses to 
determine the safe dosage range. Other key parameters include pharmacokinetic characteristics 
such as bioavailability, distribution, and half-life. Academic research centers often have clinical 
trial units, in some cases funded by their Clinical and Translational Science Award (CTSA), which 
can be ideal venues for conducting this type of research because they are staffed by research nurses 
with experience in conducting early-stage human research studies (see the chapter “Clinical and 
Translational Science Awards”). Private, for-profit clinical research organizations often conduct 
these studies as well. Phase 1 trials may take an average of one year and are seminal for deciding 
whether or not to proceed with drug development (“Drug Approvals - From Invention to 
Market...12 Years!”). 
Phase 2 Clinical Research 
Phase 2 clinical studies differ from Phase 1 in that the former involve patients with the disease of 
interest. They tend to be larger, involving up to 300 patients, and may be randomized. In some 
cases, they can be conducted at a single research site, but may often be multisite studies. A key 
goal is to determine the minimum and maximum dose of the compound, as well as potential effec-
tiveness. In some cases, especially with cancer therapeutics, a drug may have very limited Phase 
1 testing and may move quickly to Phase 2 trials. Phase 2 typically takes about two years (“Drug 
Approvals - From Invention to Market...12 Years!”). 
 
As with Phase 1 studies, Phase 2 studies can also be conducted in for-profit contract research 
organizations (CROs) and academic medical centers; CTSA awards are intended to accelerate this 
type of research as well. It is worth noting that academic medical centers can often provide a 
unique advantage when conducting Phase 2 studies: access to patients with the disease of interest. 
This is particularly relevant for rare diseases, but also applies for more common conditions (see 
the chapter on “Orphan Drugs: Understanding the FDA Approval Process”). Since subject recruit-
ment can be a major challenge for clinical trials, this can significantly enhance the ability to 
conduct Phase 2 (and 3) studies. Conflict-of-interest issues become increasingly common at this 
phase: in many cases, an academic entrepreneur who may profit financially from a compound is 
not allowed to directly recruit patients, especially from their own clinic, or perform many other 
research-related functions. 
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Phase 3 Clinical Research 
Phase 3 research consists of large, pivotal randomized trials that play a key role in establishing the 
clinical effectiveness of the compound to the FDA. Typically, there are two Phase 3 studies con-
ducted for a compound, narrowly targeting the specific indication for which the pharmaceutical 
company hopes to obtain FDA approval. The sample size can vary, but is often greater than 500 
research participants, and they are usually multisite studies due to the challenges associated with 
subject recruitment. These studies typically involve a placebo control, intent-to-treat analysis, and 
careful documentation of all adverse events. The findings are usually published in peer-reviewed 
journals by independent members of the academic community that led the research studies. Given 
the complexity and expense of Phase 3 studies, many startup companies may be acquired by a 
major pharmaceutical company after the Phase 2 research studies demonstrate efficacy and safety. 
This larger company often has the research experience and capacity to conduct the Phase 3 studies 
in a timely manner and move forward with the FDA process. Phase 3 clinical research studies 
typically require three years (“Drug Approvals - From Invention to Market...12 Years!”). 
New Drug Application 
Once the Phase 3 studies have concluded, the pharmaceutical company may elect to move forward 
with a New Drug Application (NDA) to the FDA. Preparing an NDA is a massive undertaking, 
with many NDAs consisting of over 100,000 pages of material. The NDA typically includes all 
the results of the research conducted to date, as well as information regarding planned marketing 
of the compound. As described by the FDA, this includes (Office of the Commissioner): 
● Proposed labeling 
● Safety updates 
● Drug abuse information 
● Patent information 
● Any data from studies that may have been conducted outside the United States 
● Institutional review board compliance information 
● Directions for use 
 
If all relevant components are provided, the FDA review team has 6–10 months to determine 
whether or not to approve the drug (Office of the Commissioner). As part of their review, the FDA 
will visit clinical sites that participated in the research to confirm that there was no evidence of 
fabrication of data, etc. In addition, the FDA may convene an independent advisory committee to 
obtain expert advice and public input on the compound and its planned indications for use. 
Phase 4 Research 
After approval by the FDA, the compound can be sold by the pharmaceutical company for the 
FDA-approved indications. However, the FDA may require additional research or data collection 
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to report on real-world outcomes related to the compound. These studies are referred to as “post-
marketing studies.” 
Conclusion 
Drug development is a highly regulated process that is largely defined by key FDA milestones that 
center around the investigational new drug application (IND) and the new drug application (NDA). 
Preclinical testing is crucial for IND approval, and the subsequent Phases 1–3 studies conducted 
under the IND help provide supporting evidence for the NDA. An academic entrepreneur can be 
closely involved in many of these steps, however, their institution’s conflict-of-interest guidelines 
may place significant limits on the specific tasks they are allowed to perform at each step. Frequent 
engagement with the FDA and regulatory experts is crucial for the successful navigation of this 
complex process. Often, a startup may conduct the early phases of the drug development process, 
then sell the compound or be acquired by a larger pharmaceutical company for the later phases. 
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Resources 
1. Drug Development Tools: The FDA provides a description of measures and methods that 
can facilitate the drug development process: https://www.fda.gov/drugs/development-
approval-process-drugs/drug-development-tools-ddts. 
2. The Center for Drug Evaluation and Research offers a series of helpful training courses 
and other events for small businesses: https://www.fda.gov/drugs/cder-small-business-
industry-assistance-sbia/cder-sbia-learn-webinars-conferences-trainings-upcoming-
events. 
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